Active GCA with Amaurosis Fugax or Acute Visual Loss — When Initial Glucocorticoid Treatment Has Not Achieved Remission

Clinical scenario

This protocol addresses active giant cell arteritis (GCA) presenting with acute visual loss or amaurosis fugax — a high-urgency presentation in which initial glucocorticoid therapy has been administered but full remission has not been achieved.

When initial treatment falls short

First-line management of GCA with acute visual symptoms — intravenous methylprednisolone followed by oral prednisone — targets complete remission: the absence of all clinical signs and symptoms attributable to active GCA, with normalisation of ESR and CRP. When these goals are not reached, a structured next-step protocol applies.

Next-step approach (partial overview)

Adjunctive targeted therapy with tocilizumab is a key component of the escalated approach in this setting, combined with glucocorticoid tapering. The complete regimen — including the alternative option, full sequencing, and tapering schedule — is available in the structured protocol.

Treatment goals

The target is sustained remission: no clinical signs or symptoms of active GCA, with normal acute phase reactants maintained for at least 6 months, and the ability to taper glucocorticoids to the target dose without relapse.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/annrheumdis-2019-215672

In patients with GCA with acute visual loss or amaurosis fugax, the administration of 0.25–1 g intravenous methylprednisolone for up to 3 days should be considered, because these high doses have both genomic and rapid non-genomic effects.

Adjunctive therapy should be used in selected patients with GCA (refractory or relapsing disease, the presence or an increased risk of GC related adverse effects or complications) using tocilizumab.

Methotrexate may be used as an alternative.

The treatment target is sustained remission (absence of clinical signs and symptoms of active GCA + normal acute phase reactants) plus ability to taper GCs to the specified target without relapse.

View source ↗